ArticleMycotoxin research2024
Degradation of deoxynivalenol by a microbial consortia C1 from duck intestine.
Article in Mycotoxin research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Recent advances in the mechanism of deoxynivalenol-induced hepatotoxicity and protective strategies.Archives of toxicology · 2026Review
- Black Soldier Fly Larvae Bioconvert Deoxynivalenol-Contaminated Feed Without Toxin Accumulation: Growth Performance, Residue Distribution, and Gut Microbiota Responses.Microorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Deoxynivalenol (DON), one of the most widespread mycotoxins in food and feed, poses a persistent health threat to humans and farm animals, and is difficult to eliminate. The utilization of the biotransformation mechanism by microorganisms to detoxify DON is a promising strategy. Although individual strains are capable of DON degradation, their isolation and purification are challenging and time-consuming. Recently, the microbial consortia concept has been proposed, owing to their ability to perform more complex tasks and are more tolerant to environmental changes than individual strains or species. In this study, the novel microbial consortia C1 that could efficiently convert DON to de-epoxy DON (DOM-1) was screened from the cecum contents of ducks. After 24 h anaerobic incubation, 100 μg/ml DON was completely degraded by C1. In vitro, C1 can effectively degrade DON in corn steep liquor (CSL) with an efficiency of 49.44% within 14 days. Furthermore, C1 effectively alleviated the DON poisoning in mice. After C1 treatment, the serum DON level decreased by 40.39%, and the reduction in serum total protein and albumin levels were mitigated. Additionally, C1 is effective in protecting the mouse liver against 5 mg/kg DON. These findings suggest that C1 could be a promising DON biological detoxifier and provide novel microbial resources for preventing DON contamination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.